SCHEMBL119461

SCHEMBL119461

COC(=O)c1ccc(S(=O)(=O)NCc2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.72
ALDH1A1 P00352 3/20 0.67
CA12 O43570 3/20 0.63
CA9 Q16790 3/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
ATM Q13315 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KEAP1 Q14145 1/20 0.63
TSHR P16473 2/20 0.63
CA1 P00915 3/20 0.60
CA2 P00918 3/20 0.60
CYP19A1 P11511 1/20 0.59
NAMPT P43490 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
PRMT1 Q99873 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3850206 0.94 POLB (0.72) POLBALDH1A1CA12CA9CYP1A2
SCHEMBL119672 0.90 POLB (0.70) POLBALDH1A1CA12CA9CYP1A2
SCHEMBL20981410 0.87 ALDH1A1 (0.68) POLBALDH1A1CA12CA9CYP1A2
SCHEMBL1169525 0.86 POLB (0.65) POLBALDH1A1TSHRCYP19A1NAMPT
SCHEMBL20981395 0.86 TSHR (0.80) POLBALDH1A1L3MBTL1TSHRCA1
SCHEMBL1278961 0.86 TSHR (0.80) POLBALDH1A1L3MBTL1TSHRCA1
SCHEMBL1287354 0.86 POLB (0.65) POLBALDH1A1CA12CA9CYP1A2
SCHEMBL119847 0.86 ALDH1A1 (0.68) POLBALDH1A1PRMT1SMN1; SMN2LMNA
SCHEMBL28727051 0.85 CYP19A1 (0.81) ALDH1A1CA12CA9CYP1A2CYP3A4
SCHEMBL3874748 0.83 NAMPT (0.60) POLBALDH1A1CA12CA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 POLB 4630/4885ALDH1A1 1996/4885CA12 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.